NO982418L - Betinget replikerende virale vektorer og deres anvendelse - Google Patents

Betinget replikerende virale vektorer og deres anvendelse

Info

Publication number
NO982418L
NO982418L NO982418A NO982418A NO982418L NO 982418 L NO982418 L NO 982418L NO 982418 A NO982418 A NO 982418A NO 982418 A NO982418 A NO 982418A NO 982418 L NO982418 L NO 982418L
Authority
NO
Norway
Prior art keywords
image
viral
conditionally replicating
vector
replicating viral
Prior art date
Application number
NO982418A
Other languages
English (en)
Other versions
NO329619B1 (no
NO982418D0 (no
Inventor
Boro Dropulic
Paula M Pitha
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of NO982418D0 publication Critical patent/NO982418D0/no
Publication of NO982418L publication Critical patent/NO982418L/no
Publication of NO329619B1 publication Critical patent/NO329619B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
NO19982418A 1995-11-28 1998-05-27 Betinget replikerende virale vektorer, fremgangsmate for fremstilling, sammensetninger og deres anvendelse NO329619B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56345995A 1995-11-28 1995-11-28
PCT/US1996/018997 WO1997020060A1 (en) 1995-11-28 1996-11-27 Conditionally replicating viral vectors and their use

Publications (3)

Publication Number Publication Date
NO982418D0 NO982418D0 (no) 1998-05-27
NO982418L true NO982418L (no) 1998-07-27
NO329619B1 NO329619B1 (no) 2010-11-22

Family

ID=24250568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982418A NO329619B1 (no) 1995-11-28 1998-05-27 Betinget replikerende virale vektorer, fremgangsmate for fremstilling, sammensetninger og deres anvendelse

Country Status (19)

Country Link
EP (2) EP0871757B1 (no)
JP (2) JP2000503527A (no)
KR (1) KR100537458B1 (no)
CN (3) CN1940076A (no)
AT (2) ATE455858T1 (no)
AU (3) AU1124997A (no)
BR (1) BR9612574A (no)
CA (1) CA2236868C (no)
CZ (1) CZ294170B6 (no)
DE (2) DE69626681T2 (no)
DK (1) DK0871757T3 (no)
ES (1) ES2188802T3 (no)
HK (1) HK1060152A1 (no)
IL (2) IL124636A0 (no)
NO (1) NO329619B1 (no)
NZ (1) NZ324157A (no)
PT (1) PT871757E (no)
RU (1) RU2270250C2 (no)
WO (1) WO1997020060A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037669A4 (en) * 1997-12-12 2003-04-02 Cell Genesys Inc THERAPEUTIC USE OF LENTIVIRAL VECTORS
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
EP1356070A2 (en) * 2000-09-22 2003-10-29 Virxsys Conditionally replicating viral vectors and their use
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
TR201802323T4 (tr) 2007-12-11 2018-03-21 Univ North Carolina Chapel Hill Polipürin yolu modifiye edilmiş retroviral vektörler.
MX363307B (es) * 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
CA2977687C (en) * 2015-02-24 2024-02-13 Hwai Wen Chang Conditionally active proteins
CN104711294A (zh) * 2015-04-02 2015-06-17 扬州大学 一种基于禽网状内皮组织增生症病毒ltr的真核表达线性化载体的构建方法及应用
GB2543730A (en) * 2015-05-26 2017-05-03 Andrzejewski Slawomir Use of replication competent vector to eradicate viral latency presented on human immunodeficiency virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
NZ267797A (en) * 1993-05-17 1997-09-22 Univ California Retroviral vector comprising a ribozyme capable of cleaving a hiv nucleic acid capable
ES2260376T3 (es) * 1994-01-05 2006-11-01 Gene Shears Pty Limited Ribozimas dirigidas contra una secuencia tat del vih.
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof

Also Published As

Publication number Publication date
CZ294170B6 (cs) 2004-10-13
AU1124997A (en) 1998-06-19
AU2004200663B2 (en) 2007-07-05
DE69626681T2 (de) 2004-02-12
AU767620B2 (en) 2003-11-20
EP0871757B1 (en) 2003-03-12
EP0871757A1 (en) 1998-10-21
IL124636A0 (en) 1998-12-06
EP1380650A1 (en) 2004-01-14
CN100390291C (zh) 2008-05-28
DK0871757T3 (da) 2003-07-14
PT871757E (pt) 2003-08-29
AU1000001A (en) 2001-05-17
CN1651577A (zh) 2005-08-10
NO329619B1 (no) 2010-11-22
CN1207775A (zh) 1999-02-10
CZ162498A3 (cs) 1998-12-16
BR9612574A (pt) 2000-04-25
CA2236868C (en) 2014-01-21
ATE234362T1 (de) 2003-03-15
JP2007014341A (ja) 2007-01-25
JP2000503527A (ja) 2000-03-28
ES2188802T3 (es) 2003-07-01
NO982418D0 (no) 1998-05-27
CA2236868A1 (en) 1997-06-05
JP4384146B2 (ja) 2009-12-16
CN1940076A (zh) 2007-04-04
AU2004200663A1 (en) 2004-04-08
HK1060152A1 (en) 2004-07-30
NZ324157A (en) 2000-10-27
WO1997020060A1 (en) 1997-06-05
ATE455858T1 (de) 2010-02-15
DE69626681D1 (de) 2003-04-17
EP1380650B1 (en) 2010-01-20
KR100537458B1 (ko) 2008-09-08
KR19990071728A (ko) 1999-09-27
RU2270250C2 (ru) 2006-02-20
DE69638120D1 (de) 2010-03-11
IL124636A (en) 2009-12-24

Similar Documents

Publication Publication Date Title
CY1120209T1 (el) Αλληλουχιες αδενο-εξαρτωμενου ιου (aav) οροτυπου 9, φορεις που τον περιεχουν και χρησεις αυτων
DK0836648T3 (da) Rekombinant MVA-virus og anvendelse deraf
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
CY1115405T1 (el) Αλληλουχιες κυκλοϊου που συνδyαζονται με την ασθενεια της καχεξιας του χοιριδιου (map)
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
DK0871757T3 (da) Konditionelt replikerende virale vektorer og deres anvendelse
DK0839194T3 (da) Varianter af P53-proteinet og terapeutiske anvendelser
DK0843731T3 (da) Adenovirusvektorer til genterapi
EP0789563B8 (en) Hepatitis virus b and c vaccines
DK0817859T3 (da) Rekombinante DNA vektorer til Genterapi

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees